Adherence to opioid agonist therapy predicts uptake of direct-acting antivirals in people who use drugs: results from the French national healthcare database (the ANRS FANTASIO study).
Buprenorphine
DAA
Drug use
Hepatitis C
Methadone
Journal
Harm reduction journal
ISSN: 1477-7517
Titre abrégé: Harm Reduct J
Pays: England
ID NLM: 101153624
Informations de publication
Date de publication:
27 10 2022
27 10 2022
Historique:
received:
22
05
2022
accepted:
29
09
2022
entrez:
28
10
2022
pubmed:
29
10
2022
medline:
1
11
2022
Statut:
epublish
Résumé
Opioid agonist therapy (OAT) is associated with reduced injection, reduced HCV transmission, and more opportunities to initiate hepatitis C virus (HCV) treatment in people who use drugs (PWUD). We aimed to study the extent to which adherence to OAT was predictive of increased uptake of direct-acting antivirals (DAA) in PWUD with chronic HCV infection. Using the French national healthcare system database, we targeted PWUD (i.e. with a history of OAT) who had chronic HCV infection and were eligible for DAA during 2014-2016. Adherence to OAT was computed as a time-varying variable expressing the proportion of days covered by OAT receipt, over any six-month interval before DAA receipt. We used a Cox proportional hazards model to estimate the association between adherence to OAT and the rate of DAA uptake after adjustment for age, sex, alcohol use disorder, socioeconomic status, and liver disease severity. Among the 22,615 persons included in the ANRS FANTASIO study, 3438 (15.2%) initiated DAA during the study period. After multivariable adjustment, adherence to OAT was associated with a higher rate of DAA initiation. However, this association was not linear, and only individuals on OAT for 20% or more of the time in the previous six-month period had a higher rate of DAA initiation (adjusted hazard ratio [95% confidence interval]: 1.28 [1.18-1.38]). Other variables associated with DAA initiation were male sex, older age, cirrhosis or liver cancer, and higher socioeconomic status. Adherence to OAT is a major predictor of DAA initiation in PWUD living with chronic HCV infection in France. Our results also suggest that even moderate adherence to OAT can facilitate DAA uptake. Adequate HCV training for OAT prescribers together with interventions to ensure adherence to OAT will help improve DAA initiation rates and reach HCV elimination goals.
Sections du résumé
BACKGROUND
Opioid agonist therapy (OAT) is associated with reduced injection, reduced HCV transmission, and more opportunities to initiate hepatitis C virus (HCV) treatment in people who use drugs (PWUD). We aimed to study the extent to which adherence to OAT was predictive of increased uptake of direct-acting antivirals (DAA) in PWUD with chronic HCV infection.
METHODS
Using the French national healthcare system database, we targeted PWUD (i.e. with a history of OAT) who had chronic HCV infection and were eligible for DAA during 2014-2016. Adherence to OAT was computed as a time-varying variable expressing the proportion of days covered by OAT receipt, over any six-month interval before DAA receipt. We used a Cox proportional hazards model to estimate the association between adherence to OAT and the rate of DAA uptake after adjustment for age, sex, alcohol use disorder, socioeconomic status, and liver disease severity.
RESULTS
Among the 22,615 persons included in the ANRS FANTASIO study, 3438 (15.2%) initiated DAA during the study period. After multivariable adjustment, adherence to OAT was associated with a higher rate of DAA initiation. However, this association was not linear, and only individuals on OAT for 20% or more of the time in the previous six-month period had a higher rate of DAA initiation (adjusted hazard ratio [95% confidence interval]: 1.28 [1.18-1.38]). Other variables associated with DAA initiation were male sex, older age, cirrhosis or liver cancer, and higher socioeconomic status.
CONCLUSIONS
Adherence to OAT is a major predictor of DAA initiation in PWUD living with chronic HCV infection in France. Our results also suggest that even moderate adherence to OAT can facilitate DAA uptake. Adequate HCV training for OAT prescribers together with interventions to ensure adherence to OAT will help improve DAA initiation rates and reach HCV elimination goals.
Identifiants
pubmed: 36303159
doi: 10.1186/s12954-022-00702-9
pii: 10.1186/s12954-022-00702-9
pmc: PMC9615191
doi:
Substances chimiques
Antiviral Agents
0
Analgesics, Opioid
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
119Informations de copyright
© 2022. The Author(s).
Références
J Viral Hepat. 2020 Mar;27(3):281-293
pubmed: 31698545
Rev Epidemiol Sante Publique. 2017 Oct;65 Suppl 4:S149-S167
pubmed: 28756037
BMC Infect Dis. 2017 Feb 21;17(1):162
pubmed: 28222681
Clin Infect Dis. 2021 Jul 1;73(1):e107-e118
pubmed: 32447375
Drug Alcohol Depend. 2021 Nov 1;228:109050
pubmed: 34607193
Int J Drug Policy. 2019 Oct;72:61-68
pubmed: 31129024
Addiction. 2020 Mar;115(3):573-582
pubmed: 31595554
PLoS One. 2018 Mar 26;13(3):e0194162
pubmed: 29579073
Pharmacoepidemiol Drug Saf. 2021 Jan;30(1):86-96
pubmed: 33090666
Lancet Glob Health. 2017 Dec;5(12):e1208-e1220
pubmed: 29074410
Drug Alcohol Depend. 2021 Mar 1;220:108525
pubmed: 33461152
Liver Int. 2019 Dec;39(12):2418-2419
pubmed: 31436366
Clin Infect Dis. 2022 Mar 1;74(4):575-583
pubmed: 34125883
Clin Infect Dis. 2021 Jul 1;73(1):e69-e78
pubmed: 32421194
Liver Int. 2016 Jan;36 Suppl 1:47-57
pubmed: 26725897
BMC Infect Dis. 2020 Oct 15;20(1):759
pubmed: 33059617
Rev Epidemiol Sante Publique. 2016 Sep;64(4):301-12
pubmed: 26904917
PLoS One. 2014 Nov 13;9(11):e112328
pubmed: 25393311
J Viral Hepat. 2021 May;28(5):739-754
pubmed: 33556225
Harm Reduct J. 2013 May 07;10:7
pubmed: 23651646
Epidemiol Infect. 2008 Jul;136(7):865
pubmed: 18482461
Lancet. 2022 Jan 1;399(10319):61-116
pubmed: 34863359
PLoS One. 2016 Jun 13;11(6):e0157062
pubmed: 27294271